February 7, 2007. — More than ninety percent of men who receive “appropriate ” radiation dose levels with permanent radiation seed implants to treat their early-stage prostate cancer remain recurrence-free eight years after diagnosis, according to a study released in the February 1 issue of the International Journal for Radiation Oncology*Biology*Physics, the official journal of ASTRO.

“The only controllable factor to impact on long-term outcome,” the study states, “was the D90 which is a reflection of implant quality.” Whether the isotope used to achieve adequate dose was iodine 125 (I-125) or palladium 103 (P-103) “was not significant,” the study found. Full Story:
If Dose is Right, Radioactive Seed Implant for Early-Stage Prostate Cancer Has High Odds of Success

January 5, 2007. Seventy-four percent of men treated with a combination of radiation seed implants and external beam radiation therapy for prostate cancer are cured of their disease 15 years following their treatment, according to a study released today in the International Journal of Radiation Oncology*Biology*Physics, the official journal of ASTRO.

“This study is exciting because it shows that the combination of brachytherapy and external beam therapy are successful long-term at curing men of their prostate cancer,” said lead autor John E. Sylvester, M.D. Full story ….

“Two battling cancer sufferers have left their sick beds to join forces in a demand for better treatment for cancer patients in Wales.

Grandfather Dave Powell and mother-of-two Jayne Sullivan, who are still receiving treatment for their cancers, are taking their protest to the National Assembly with a claim that Welsh patients are being victimised.

Both are urging that cancer treatments and the drugs involved should be available to all patients who need them.

Earlier this year, breast cancer victim Mrs Sullivan, 45, highlighted the NHS restrictions on the use of the breast cancer drug herceptin by staging a seven-day sit-in protest at the assembly.

Grandfather Mr Powell, 54, of Barry, had been fighting since March for treatment for his prostate cancer and finally received help from a hospital in England last month.

But the couple say other prostate cancer sufferers who have been recommended for similar therapy, which is not available in Wales, have been told they will only receive in exceptional circumstances. This has been confirmed in a letter to doctors

Mr Powell said: ‘I eventually received treatment but only after a five-month battle with NHS officials in the National Assembly.

‘This form of treatment - brachytherapy - is a low-dose form of radiotherapy and has been available for years in the UK but not in Wales. They are now telling other Welsh men in my situation they will not pay for prostate cancer patients to receive help in England - that’s a disgrace.’

by Greg Tindle, South Wales Echo, Sept 19 2006
icwales.co.uk

Obese men with prostate cancer are at higher risk for treatment failure after primary radiation therapy, according to a new study from M. D. Anderson.

Full story

COX-2 inhibitors are a class of drugs that have been shown to have some anti-tumor activity against human prostate cancer, both in the lab and in tests on humans. German researchers wanted to find out if combining COX-2 inhibitors with radiation therapy causes more severe side effects than radiation alone. They conducted a Phase I trial to test this.
(full story…)

Nicholas DeWolf, inventor, computer expert and philosopher, died Sunday April 12 in a hospital in Aspen, CO age 77 of complications from a stroke and prostate cancer.

Chad Abraham in the Aspen Times, April 17 called Nicholas DeWolf “an extraordinary and exuberant spirit of Aspen whose work in the semiconductor field paved the way for today’s computer industry.”

“He was an engineer, he emphasized in Greg Poschman’s induction video for the Aspen Hall of Fame,” Abraham goes on, “not a scientist.”

“But he was also a husband, father, actor, inventor, photographer and a sensualist; an animal lover who was loved by animals, a provocateur, skier, and an eccentric whose office suffered, or benefited from, legendary disorganization.”

“DeWolf, those close to him say, fought hard for Aspen’s preservation as the perfect world for providing absolute freedom of the discussion of ideas and the ability to mingle across classes, dishwashers to debutantes, Hollywood stars to ski bums.”

Nick DeWolf was diagnosed with prostate cancer in 1996. On a website he created that year, PROSTATE CANCER meets PROTON BEAM ! A Patient’s Experiences, he wrote: “Hmm… Age 68, PSA=12, Gleason Score=7, Stage B1. Determined not to die of Prostate cancer, hoping to preserve sexuality. What to do, where to go?? ”

After researching all treatments available at the time, talking to doctors and to patients and considering effects of hormonal blockade on male sexuality, DeWolf opted for Proton beam radiation at Loma Linda.

Michael Bard, who told us about Nick’s death yesterday, wrote:

“I was deeply saddened to learn of Nick DeWolf’s passing on April 12th. Nick and I never met, but we chatted many times. When I was first diagnosed in 1999, I wrote to Nick and he immediately called me. We had several marathon conversations and he never was too busy to share his compassion and his knowledge.

His joie de vie was infectious. I remember his excitement over recording the Vietnamese hill tribes. Even when he had a recurrence, he continued to support Proton Beam and LLUMC. I put him in touch with men who were exploring salvage options and never dreamed his disease would progress so aggressively.

The Cap community is better for his presence. In the end, none of us can have a better tribute than that they helped their fellow man. I will miss him.”

Links
Nick DeWolf’s websites and photography — Images by Nick DeWolf
Press source including the photo
Computer pioneer dies at 77: Nick DeWolf’s genius illuminated, soaked Aspen. By Chad Abraham, Aspen Times, April 17, 2006